menu
    • menu
    [{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Velusetrag","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Alfasigma","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Alfasigma"}]

    Find Clinical Drug Pipeline Developments & Deals for Velusetrag

    Menu

    Velusetrag

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alfasigma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Alfasigma

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

                            Details : Velusetrag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Pseudo-Obstruction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

                            Details : Velusetrag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastroparesis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2014

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

                            Details : Velusetrag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastroparesis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 01, 2012

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theravance Biopharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

                            Details : Velusetrag is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2011

                            Lead Product(s) : Velusetrag

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth